Benchmark Lowers Abbott Laboratories (NYSE:ABT) Price Target to $120.00

Abbott Laboratories (NYSE:ABT) had its target price dropped by investment analysts at Benchmark from $145.00 to $120.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the healthcare product maker’s stock. Benchmark’s target price suggests a potential upside of 23.85% from the company’s current price.

A number of other research analysts also recently commented on ABT. The Goldman Sachs Group reduced their target price on Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating on the stock in a report on Wednesday, April 8th. Royal Bank Of Canada reduced their target price on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Argus reduced their target price on Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Leerink Partners reduced their target price on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a report on Friday, January 30th. Finally, Daiwa Securities Group reduced their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average target price of $121.00.

Abbott Laboratories Trading Up 1.5%

Shares of ABT opened at $96.89 on Friday. The company has a market capitalization of $168.75 billion, a P/E ratio of 27.14, a P/E/G ratio of 1.57 and a beta of 0.79. Abbott Laboratories has a one year low of $93.92 and a one year high of $139.06. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The stock has a 50-day moving average price of $107.89 and a 200 day moving average price of $118.65.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.Abbott Laboratories’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the sale, the executive vice president directly owned 146,377 shares in the company, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the sale, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 3,055 shares of company stock worth $353,097. Corporate insiders own 0.46% of the company’s stock.

Institutional Trading of Abbott Laboratories

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Gemmer Asset Management LLC raised its position in shares of Abbott Laboratories by 2.9% during the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock worth $368,000 after purchasing an additional 78 shares during the period. Global Financial Private Client LLC raised its position in shares of Abbott Laboratories by 3.3% during the 3rd quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after purchasing an additional 79 shares during the period. Citizens & Northern Corp raised its position in shares of Abbott Laboratories by 0.4% during the 3rd quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock worth $2,930,000 after purchasing an additional 79 shares during the period. American National Bank of Texas increased its position in Abbott Laboratories by 2.4% in the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock valued at $427,000 after acquiring an additional 79 shares during the period. Finally, Nia Impact Advisors LLC increased its position in Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after acquiring an additional 79 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Preliminary settlement reached in six shareholder derivative suits tied to Abbott’s U.S. infant‑formula business, reducing litigation overhang for investors. Read More.
• Positive Sentiment: New data on Cancerguard MCED (multi‑cancer early detection) presented at AACR 2026 — important for Abbott’s growth thesis since the Exact Sciences deal expanded its oncology diagnostics exposure. Continued clinical progress supports longer‑term revenue upside. Read More.
• Positive Sentiment: Insiders added roughly $3.1M of stock, and a number of analysts still see upside — some calling the post‑acquisition pullback a buying opportunity given valuation and Abbott’s dividend track record. Read More. Read More.
• Neutral Sentiment: Q1 results: adjusted EPS $1.15 (vs. $1.14 est.) and revenue $11.16B (vs. $10.99B); company set FY 2026 adjusted EPS guidance to $5.38–$5.58 and Q2 guide to $1.25–$1.31, explicitly including ~$0.20 of dilution from the Exact Sciences acquisition. Investors are parsing beat vs. the guidance change. Read More.
• Neutral Sentiment: Earnings call transcript and analyst commentary emphasize medical‑device strength offset by Diagnostics/Nutrition softness and acquisition-related margin pressure — useful for active traders but mixed for near‑term stock direction. Read More.
• Negative Sentiment: Market reaction: shares fell after the print because Abbott trimmed guidance and flagged Nutrition weakness and margin compression; coverage shows the takeover (≈$21–23B) is dilutive near term. Read More.
• Negative Sentiment: Many brokers lowered price targets and some cut forecasts following Q1/guidance — several firms kept positive ratings but reduced targets (examples include RBC, Jefferies, Raymond James, Citi and others), amplifying short‑term selling pressure. Read More.
• Negative Sentiment: Analyst notes and headlines highlighted the EPS guidance cut and Nutrition slump as primary reasons for the earlier drop — these remain catalysts to watch for the next quarter. Read More.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.